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Abstract
Background: Many analyses of HIV treatment decisions assume a fixed formulary of HIV drugs. However, new drugs are
approved nearly twice a year, and the rate of availability of new drugs may affect treatment decisions, particularly when to
initiate antiretroviral therapy (ART).
Objectives: To determine the impact of considering the availability of new drugs on the optimal initiation criteria for ART
and outcomes in patients with HIV/AIDS.
Methods: We enhanced a previously described simulation model of the optimal time to initiate ART to incorporate the rate
of availability of new antiviral drugs. We assumed that the future rate of availability of new drugs would be similar to the
past rate of availability of new drugs, and we estimated the past rate by fitting a statistical model to actual HIV drug
approval data from 1982–2010. We then tested whether or not the future availability of new drugs affected the model-
predicted optimal time to initiate ART based on clinical outcomes, considering treatment initiation thresholds of 200, 350,
and 500 cells/mm3. We also quantified the impact of the future availability of new drugs on life expectancy (LE) and quality-
adjusted life expectancy (QALE).
Results: In base case analysis, considering the availability of new drugs raised the optimal starting CD4 threshold for most
patients to 500 cells/mm3. The predicted gains in outcomes due to availability of pipeline drugs were generally small (less
than 1%), but for young patients with a high viral load could add as much as a 4.9% (1.73 years) increase in LE and a 8%
(2.43 QALY) increase in QALE, because these patients were particularly likely to exhaust currently available ART regimens
before they died. In sensitivity analysis, increasing the rate of availability of new drugs did not substantially alter the results.
Lowering the toxicity of future ART drugs had greater potential to increase benefit for many patient groups, increasing
QALE by as much as 10%.
Conclusions: The future availability of new ART drugs without lower toxicity raises optimal treatment initiation for most
patients, and improves clinical outcomes, especially for younger patients with higher viral loads. Reductions in toxicity of
future ART drugs could impact optimal treatment initiation and improve clinical outcomes for all HIV patients.
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Introduction
The timing of HIV therapy initiation has been controversial,
and remains so in resource-limited settings.[1,2,3,4] In June 2013,
the World Health Organization (WHO) updated its recommen-
dation regarding the time to initiate therapy, now recommending
an earlier initiation of ART when the CD4 count falls below
500 cells/ml. [5] Because timing decisions are not amenable to
randomized controlled trials, this problem has been widely
modeled and discussed in published reports.[6,7,8,9,10,11] These
models generally seek to identify the clinical conditions under
which a patient should initiate ART so as to maximize his/her
quality-adjusted life expectancy, and consider many factors, such
as the initial viral load and CD4 count, age, gender, CD4
threshold and viral load threshold for initiating drugs, adherence,
resistance, and HIV mutations at baseline. However, these models
have not considered the rate of development of new antiretroviral
drugs. In contrast, they have assumed fixed numbers of
antiretroviral drugs assigned to a fixed number of distinct
mechanistic categories, an unrealistic assumption because a
pipeline of new ARTs is likely to continue. More ART options
could make earlier initiation more favorable, because it could
reduce the risk of accruing resistance to all available regimens.
Additionally, newer ART regimens could be less toxic, also shifting
the balance in favor of earlier ART. While ART initiation on
detection has been advocated on the grounds of reducing the
epidemic impact, this suggestion may not be persuasive for
individuals who maximally value their health and well-being over
those of the population at large.
Accordingly, we developed a model to address how ART
initiation recommendations would change with varying assump-
tions regarding the rates of new drug development, the proportion
of new drugs in existing classes versus new mechanistic classes, the
patterns of cross-resistance between new and existing mechanistic
classes, the efficacy of pipeline drugs compared to existing drugs,
and the toxicity of new drugs compared to existing drugs.
Methods
We adapted the well-validated HIV simulation model of
Braithwaite et al.[6] to consider different assumptions regarding
the availability and characteristics of new antiretroviral drugs. The
Braithwaite model has been described in detail else-
where,[6,12,13] but will be briefly described here. A graphical
representation with further explanation is provided in Appendix
S1. The model is an individual microsimulation that tracks the
individual progression of disease (CD4 counts, viral loads,
presence of mutations, treatment status, etc.) and estimates HIV-
related mortality as a function of those individual patient
characteristics.[12] It estimates baseline non-HIV mortality as a
function of age and gender, HIV-related mortality is a function of
CD4 count, and mortality is also affected by the toxicity of ARVs.
The rate of decline in CD4 count is a function of the current VL,
the presence of treatment and demographic factors. A notable
aspect of the model is the mechanistic manner by which the model
represents the development of HIV antiviral resistance.[12,13,14]
Each individual in the model has a simplistic representation of the
viral genome which mutates as a function of replication rate, and a
mutation becomes established in the population only of a mutation
occurs to a drug that the patient is on, providing selection pressure.
Effective ART therapy decreases the replication rate, which
decreases the mutation rate. Once a mutation becomes estab-
lished, the replication rate and VL increase, and the CD4 count
declines. The model has been demonstrated to predict the time to
treatment failure, survival, and the development of HIV antiviral
resistance.[6,13,15]
We modified this model by incorporating the arrival of new
drugs, both within existing classes of drugs and the development of
new classes of antiretroviral agents. This modification allows the
simulation to treat patients with more cycles of therapy, and
provides increased flexibility for changing to a different drug
combination after the development of resistance.
In our base case, we simulated a cohort of patients treated under
the assumption of the availability of three classes of antiretroviral
drugs, without the future development of new drugs, which is a
common assumption used by most HIV treatment models.[1,6]
We then compared the life expectancy and quality-adjusted life
expectancy of an identical cohort treated under alternative
scenarios that assumed new ART drugs would become available,
seeking to estimate how this ART pipeline would influence the
optimal criteria for ART initiation. Because of considerable
uncertainty regarding the effectiveness and toxicity of new drugs,
we explored a wide variety of assumptions. However, we centered
these assumptions on historical data describing the arrival rate of
ART drugs for both existing and new classes of drugs, and the
likelihood of cross-resistance between new and existing mechanis-
tic classes.
Estimating the arrival rate of new ART drugs
We fit the probability distribution for the arrival of new ART
drugs, defined as when the drug was approved by the Food and
Drug Administration (FDA), to an exponential distribution using
data from the FDA of the approval date of each drug and each
new drug class (see Table A1 and A2 in Appendix S1).[16] The
parameters of distributions were estimated by the Maximum
Likelihood Estimator technique. Goodness of fit was tested by
Quantile-Quantile plot and Kolmogorov-Smirnov tests.[17] The
statistical programming language ‘‘R’’ was used for all estimates
and statistical tests.
An exponential inter-arrival time implies that the number of
new events in a given time will follow a Poisson process. We
assumed that the new drug arrival was a combination of two
processes: 1) the arrival process of new classes of drugs, and 2) the
arrival process of new drugs belonging to existing classes. We fit
the arrival process of drugs to a split Poisson process, meaning that
the arrival of new classes is independent from the arrival processes
of drugs within an existing class.[18] Moreover, if a new drug
arrived belonging to an existing class, we assumed that it will be
uniformly distributed among current classes. A schematic view is
shown in Figure 1. See Table A1 in Appendix S1.
Estimating Cross-resistance of new antiretroviral agents
The development of HIV antiviral resistance is complex, and
mutations in the HIV genome that confer resistance to a particular
drug may also confer partial resistance to other drugs. Since cross
resistance may affect new drugs as it does existing ones, we
modeled the probability that new drugs would confer cross
resistance. Empirically, cross resistance is substantially more likely
in drugs within the same class than between drugs of a different
class.[19] For example, mutations in the NRTI and NNRTI class
are both in the Reverse Transcriptase gene, but there is no mutual
mutation between these classes, so there is no cross-resistance
pattern between the NRTI and NNRTI classes. Since mutations
in the PI class occur in the Protease gene and in the NRTI and
NNRTI class occur in Reverse Transcriptase gene,[19] there is no
cross-resistance between these classes either.
The cross resistance of new drugs within a class is assumed to be
equal to the distribution of cross-resistance patterns of existing
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drugs, i.e., if a new drug belongs to the NRTI class, it will follow
the resistance pattern of the NRTI class. The probability that a
specific mutation will confer resistance to a new drug is estimated
by the proportion of drugs in that class for which the mutation is
known to confer resistance. For example, in the NRTI class, the
M41 mutation confers resistance only to Stavudine and Zidovu-
dine, so the total number of drugs for which M41 confers
resistance is 2 out of 7 drugs.[19] This procedure was repeated for
all mutations in each class. Then, the best-fitting probability
distribution was determined based on the number of drugs to
which each mutation confers resistance.
The efficacy and toxicity of new antiretroviral agents
The efficacy of a particular drug is represented by its ability to
decrease viral load under perfect adherence. Our baseline
assumption is that efficacy of new drugs (the viral load decrement
at perfect adherence) is equal to the average of viral load
decrements observed by drugs in the same class as the new drug,
under scenarios of near-perfect adherence. In our base case
analysis, we assume that the toxicity of new drugs was similar to
the toxicity level of existing drugs within that category. However,
in sensitivity analysis we explore scenarios in which the efficacy
and toxicity of pipeline drugs are different from existing drugs.
Scenarios regarding when to initiate ART
Successive populations of individuals with newly diagnosed
chronic HIV infection were considered, each of them starting with
CD4 count of 500 cells/mm3. We considered alternative CD4
thresholds for ART initiation varying from 50 cells/mm3 to
500 cells/mm3, in increments of 50 cells/mm3. In addition,
different starting age categories (30, 40, and 50) and baseline
viral loads of 104, 104.5, 105 and 105.5 copies/mL were modeled.
In each scenario, the optimal CD4 count at which to initiate
treatment was identified by finding the CD4 count (up to 500 cell/
mm3) that produced the maximum life expectancy. Additionally,
in each scenario, we compared increases in life expectancy (LE)
and quality-adjusted life expectancy (QALE) that could arise from
the expected rate of development of new ARTs.
Sensitivity analyses
We varied several assumptions to assess robustness of model
predictions, particularly regarding the pipeline of new ART drugs.
Specifically, we varied the inter-arrival time of new drugs, the rate
at which new drugs induce resistance mutations, the propensity to
adhere with ART overall, the effectiveness of new pipeline drugs
compared to existing drugs, and the toxicity level of new pipeline
drugs compared to existing drugs. In scenarios in which the
efficacy of the new drug is equivalent to the average of the existing
Figure 1. Arrival process of pipeline drugs. The arrival process of HIV pipeline drugs follows a split Poisson process. See text for details.
doi:10.1371/journal.pone.0098354.g001
Table 1. Inter-arrival time distributions.
Probability distribution P-value 95% CI
Inter-arrival time of new drugs Exponential (l~0:13) 0.085 [0.09,0.181]
Inter-arrival time of new classes Exponential (l~0:02) 0.725 [0.006,0.041]
Inter-arrival time of new drugs belonging to existing classes Exponential (l~0:104) 0.112 [0.068,0.147]
A Poisson process produces exponential inter-arrival distribution.
doi:10.1371/journal.pone.0098354.t001
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drugs, the new drug is added as an extra regimen when the patient
has exhausted all existing regimens. However, in sensitivity
analysis where the new drug is more effective than existing drugs,
we assume the new drug is used after the first regimen has failed.
Results
The arrival rate of new ART drugs
The distribution of inter-arrival times of drugs was satisfied by
assuming an exponential distribution with a mean inter-arrival
time of 7. 69 months (e.g. mean 1l~7:69 months, which implies
that the arrival of new drugs follows a Poisson process with rate
l~0:13; quantitle-quantile plot shown in Figure S3 of Appendix
S1). When a new drug arrives, its arrival time was fit by a split
Poisson process, meaning that it would be from a new class with
probability p (which we estimated at 0.194) and from current
classes with probability 1{pð Þ (which we estimated at 0.806). The
Kolmogorov-Smirnov (KS) goodness of fit test associated with
these distributions is shown in Table 1.
The distribution of new drugs between existing classes
and new classes
Between 21 June 1996 and 13 March 2003 there was 3 classes
of ART drugs, and 11 new drugs became available, of which 4
belonged to the PI class, 5 belonged to the NRTI class and 2
belonged to the NNRTI class. Fitting a uniform distribution to this
data has the p-value = 0.08253, supporting the assumption that
new drugs are distributed equally among existing classes.
The cross resistance rates of new drugs
The best fitting distributions for the probability of cross
resistance within NRTIs and NNRTs were also uniform, whereas
the probability of cross resistance within PIs was best fit by a
Poisson distribution (Table 2). The cross-resistance probability was
estimated at 0.2 between TAM and Non-TAM variants of NRTIs.
Note that for Fusion Inhibitors, Entry Inhibitors, and Integrase
Inhibitors no distribution could be fit since there was only one
drug in each class at the time of analysis. Although the KS tests for
these distributions have a p-value that indicates the empiric
distribution is statistically different from the estimated distribution,
these are the distributions with the ‘‘best’’ fit – no other
distribution had a larger p-value.
The effect of new ART drug arrival on time to initiate
therapy and clinical outcomes
Table 3 shows the optimal CD4 count threshold for initiating
ART, comparing scenarios with versus without the rate of accrual
of new ART drugs that we estimated above. Simulations with and
without pipeline drugs suggested that treatment at a CD4 count of
500 cells/mm3 was preferred for all patients except for those with
advanced age and/or low viral load which is consistent with the
new WHO guidelines. For these patient subgroups, earlier
initiation was only preferred when considering the likely ART
pipeline, whereas later initiation was preferred when considering
only the formulary of currently available drugs. In general, the
effects of the availability of pipeline drugs are small (Figure 2). New
ART drugs are most likely to add health benefits for younger
individuals with higher viral loads, which is intuitive because these
individuals are more likely to ‘‘burn through’’ existing regimens
before they die of non-HIV-related causes. Indeed, the availability
of pipeline drugs added as much as 4.9% to life expectancy (8.0%
to QALE) for 30 year-olds with the highest viral loads (.5.5 log)
for therapy initiated late (starting at 200 cells/mm3). However, the
life expectancy gains to pipeline drugs for most patients remain less
than 1%.
Sensitivity analyses
Our sensitivity analyses (Table 4) indicate that varying the
estimates of the inter-arrival times of new drugs, the rate of
accumulation of resistance, the patient’s adherence to treatment
regimens, and the relative efficacy of pipeline drugs have little
effect on overall outcomes, but that the toxicity of pipeline drugs
has a potentially large effect on life expectancy. If the toxicity of
pipeline drugs is reduced compared to existing drugs (the pipeline
Table 2. Resistance distributions for existing drug classes.
Drug class
NRTI NNRTI PI
Number of drugs 7 3 8
Probability distribution of number
of drugs resistant to a mutation
Uniform[1,4]
(p-value* = 0.059)
Uniform[1,3]
(p-value = 0.042)
Poisson(l~3)
(p-value = 0.024)
* p-value is for the for Kolmogorov-Smirnov goodness of fit test.
doi:10.1371/journal.pone.0098354.t002
Table 3. The optimal CD4 count threshold for initiating therapy.
Age 30 years Age 40 years Age 50 years
Log VL No Pipeline Pipeline No Pipeline Pipeline No Pipeline Pipeline
4.0 450 500 350 500 350 450
4.5 450 500 500 500 450 500
5.0 450 500 500 500 450 500
5.5 450 500 500 500 500 500
doi:10.1371/journal.pone.0098354.t003
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drugs have a mortality relative risk of 1), the presence of new
pipeline drugs can increase the quality-adjusted life expectancy by
as much as 11% in young patients with high viral load. Figure 3
shows the change in LE and QALE (in percent) due to the
presence of pipeline drugs for a variety of toxicity, age, and viral
load category. Aligned with the new WHO recommendation we
consider the CD4 threshold of 500 cells/mL for treatment
initiation.
Discussion
Consistent with current treatment recommendations, the base
case model (that does not include the availability of pipeline drugs)
supports early treatment in most scenarios. The addition of
pipeline drugs raises the CD4 threshold for treatment in several
classes of patients, resulting in the optimal CD4 to initiate
treatment across virtually all ages and viral loads to be 500 cells/
mm3, which supports the current WHO recommendations.
Figure 2. Percent change in outcomes from the presence of pipeline drugs by age, viral load, and CD4 count at initiation of
therapy. The graphs on the left depict the percent change in life expectancy from the presence of pipeline drugs, the graphs on the right the
percent change in quality-adjusted life expectancy.
doi:10.1371/journal.pone.0098354.g002
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However, the overall impact of a pipeline of new drugs is not large
for most patient groups, with average changes in life expectancy
less that 1%, except for patients who are young and have high viral
loads, primarily because there are already a large number of
regimens available. Our results are supported by intuition, which
would suggest that the availability of more drugs would reduce the
likelihood of ‘‘burning through’’ existing regimens for patients at
highest risk for doing so, in particular patients with higher baseline
viral loads.
Our analysis does indicate that patients will be better served if
new HIV drugs are found with lower side effects and toxicities: this
remains one of the most important reasons that drug regimens are
discontinued, and decreased toxicities and side effects will extend
the duration of the regimen.
Figure 3. Sensitivity analysis of effect percent change in LE and QALE from the presence of pipeline drugs by age, viral load, and
toxicity. The graphs on the left depict the percent change in life expectancy assuming new drugs have a lower toxicity than existing drugs (top),
identical toxicity to existing drugs (middle) or a higher toxicity that existing drugs (bottom). The graphs on the right depict the percent change in
quality-adjusted life expectancy for the same toxicity levels.
doi:10.1371/journal.pone.0098354.g003
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This study has several limitations. Our data are from a cohort
that is overwhelmingly male, and thus our results may not apply
for women. Cost or cost-effectiveness has not been considered in
our analyses, which may have impact on policy recommendations.
Our model does not include spreading of resistance patterns in the
native viral population. As resistance spreads, some newly infected
individuals may be infected with already resistant (non- ‘‘wild
type’’) strains. In addition, our analysis does not consider the
impact of pipeline drugs on the epidemic – the model does not
represent transmission between individuals. To the extent that new
pipeline drugs will lower the VL of some individuals, it would be
expected to decrease transmission. However, because the addition
of pipeline drugs extends the ability to have effective treatment
towards the end of a patient’s disease, the effect is expected to be
small. Finally, we did not perform subgroup analyses for patient
groups likely to have poor adherence (e.g. persons with substance
abuse, unhealthy alcohol use, or mental illness), who might be
more likely to exhaust existing regimens because of resistance or
intolerance, and who therefore would yield disproportional
advantages from the development of new drugs. In summary,
our results suggest that the rate of development of new ART drugs
may not impact the starting threshold for most patient groups,
although they may substantially increase benefit for younger
patients with higher viral loads. Finally, our sensitivity analyses
raise the intriguing prospect that reducing the toxicity profile of
new ART drugs may have a greater beneficial impact on health
than increasing the supply of new drugs with novel mechanisms or
resistance patterns.
Supporting Information
Appendix S1 Contains Figure S1, Basic structure of HIV
simulation model. See text for details. Figure S2, Typical patient
histories with and without pipeline drugs. See text for details.
Figure S3, The Quantile-Quantile plot for pipeline arrival process.
Quantile-Quantile plots are used to compare a dataset to a
theoretical distribution. It provides an assessment of graphical
goodness of fit. If the points lie on the line, the probability
distribution is acceptable.
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